Blood product

Therapeutic Plasma Exchange Market is Anticipated to Reach USD 2.9 billion, at a CAGR of 7.5% CAGR by 2031 - Report by Transpaency Market Research Inc.

Retrieved on: 
Wednesday, December 13, 2023
Conditional sentence, Prevalence, Hematologic disease, Qatar Red Crescent Society, Hepatology, Kidney, Incidence, Plasma, DSM-IV codes, Patient, Research, Research report, TPE, American Heart Association, Plasmapheresis, Growth, Hospital, Pharmaceutical industry, Generic drug, Blood product, Medical device

WILMINGTON, Del., Dec. 13, 2023 /PRNewswire/ -- The therapeutic plasma exchange market was valued at US$ 1.5 billion in 2022. According to estimates, the market will reach US$ 2.9 billion by the end of 2031, growing at a CAGR of 7.5%.Due to the increasing prevalence of autoimmune diseases worldwide, plasma exchange has become a popular therapeutic intervention. Myasthenia gravis and Guillain-Barré syndrome are two neurological disorders commonly treated with therapeutic plasma exchange. A major driver of the market is the use of therapeutic plasma exchange in treating these conditions.

Key Points: 
  • Therapeutic plasma exchange market growth has been driven by improvements in healthcare infrastructure and the availability of advanced medical treatments in emerging economies.
  • The increasing prevalence of neurological disorders and autoimmune diseases will likely drive the therapeutic plasma exchange market.
  • As the therapeutic plasma exchange market grows, North America is expected to hold the largest market share.
  • Global Therapeutic Plasma Exchange Market: Regional Landscape
    North America is expected to dominate the market for therapeutic plasma exchange market.

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Retrieved on: 
Thursday, November 2, 2023
Trial of the century, OH, Event, Safety, Sickle cell disease, Society, ASH, Senior, American Society of Pediatric Hematology/Oncology, Caregiver, Fetal hemoglobin, Editas Medicine, Patient, Blood, Pharmaceutical industry, Nursing, Blood product, Edith A. Perez

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patients with transfusion-dependent beta thalassemia has been accepted for a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA, and online.

Key Points: 
  • Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m.
  • Editas Medicine will also host a Company-sponsored webinar on Monday, December 11, at 1:00 p.m.
  • ET to discuss the RUBY and EdiTHAL clinical data.
  • Clinical data on six patients, including at least five months data from the first two patients treated.

Iteld Plastic Surgery Launches New Aesthetics Website

Retrieved on: 
Tuesday, October 31, 2023
Fibrin, Patient, Ageing, Plasma, Platelet-rich fibrin, Exosome, Skin, Protein, Elastin, PRF, Collagen, Regeneration, Platelet-rich plasma, Blood, PRP, Serum albumin, Dentistry, Blood product, Cosmetics

The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.

Key Points: 
  • The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.
  • Patients who are seeking other types of surgical and non-surgical cosmetic procedures can find more details on various options on the main Iteld Plastic Surgery website.
  • For more information on natural non-surgical skin rejuvenation treatments, contact Chicago’s Iteld Plastic Surgery.
  • Call (312) 757-4505, fill out a contact form to schedule a consultation, or visit the Iteld Aesthetics Institute site for more details.

Global Plasma Fractionation Market Valued at $5 Billion in 2023, Expected to Surge with 10% CAGR by 2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Health, Pharmaceutical, Government, Partnership, COVID-19, Pharmacy, Prevalence, CSL, Therapy, Primary immunodeficiency, Ageing, Protease, Rare, Takeda Pharmaceutical Company, Type, Antibody, Collection, Bio Products Laboratory, Growth, Takeda, BPL, Patient, Albumin, Blood product, Rare-earth element, Pharmaceutical industry, Sintering, Grifols, Plasma

The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.

Key Points: 
  • The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.
  • Plasma Collection Centers in the US: Currently, the United States is home to approximately 80% of the world's plasma donation centers.
  • The country supplies over 70% of the plasma used in the manufacturing of plasma-derived therapies through the process of plasma fractionation.
  • Importance of Plasma Fractionation: Plasma fractionation is a critical process for separating and purifying key blood plasma components, including immunoglobulins, albumins, anticoagulant factors, and protease inhibitors.

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Other Health, Emergent BioSolutions, Albumin, Bleeding, Prevalence, Accident, Neurogenesis, Antibody, RFID, Takeda Pharmaceutical Company, New York Blood Center, Cancer, Ageing, Emergent, Octapharma, Research, Coagulopathy, LFB, Organization, Plasma, Death, CSL Limited, Hemoglobinopathy, Von Willebrand disease, Patient, Blood, Hematology, Growth, Conditional sentence, WHO, Blood volume, Haemophilia A, Trauma, Blood product, Pharmaceutical industry

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.

Younger Generations: Key Drivers of the Global Blood Plasma Market in 2023 - Insights on Immunoglobulins, Coagulation Factors, and Albumin-derived Therapies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 15, 2023
Health, Other Health, Prevalence, Antibody, Hospital, Infection, DSM-IV codes, Ageing, Factor IX, Haemophilia, Multiple sclerosis, Plasma, Patient, Developed country, Application, VIII, Blood, Cancer, Conditional sentence, Growth, Immunodeficiency, Injury, Blood product, Hypogammaglobulinemia

By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others.

Key Points: 
  • By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others.
  • Immunoglobulin products are derived from blood plasma and are used to treat various medical conditions, including immune deficiencies, autoimmune diseases, and certain infections.
  • By Application: The global blood plasma market can be divided into four segments on the basis of application: Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia and Other.
  • By End User: The report divides the global blood plasma market into three end users: Hospitals, Clinics and Others.

Terumo Blood and Cell Technologies' Reveos® Automated Whole Blood Processing System Cleared by FDA for U.S. Commercial Use

Retrieved on: 
Tuesday, August 1, 2023
RBC, Food and Drug Administration, Cancer, Apheresis, Terumo, Plasma, Patient, Investment, Collection, Blood, Horizon Fuel Cell Technologies, FDA, Trauma, Food, Medical device, Blood product, Pharmaceutical industry

LAKEWOOD, Colo., Aug. 1, 2023 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT) announces U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole blood into platelets and other components in a single centrifugation cycle. Automated processing of whole blood on the Reveos system, the only device of its kind globally, will enhance the blood and platelet supply for patients in the U.S.

Key Points: 
  • [2] FDA's clearance of the automated Reveos system gives blood centers the added capacity to collect platelets from existing whole blood donations efficiently.
  • In Reveos, Terumo BCT brings to the U.S. a platform with an established track record following deployment in 52 countries over the past decade.
  • Reveos is the only automated device to process whole blood into platelets, plasma and red blood cell (RBC) components in a single centrifugation cycle.
  • By automating whole blood processing, Reveos can reduce the working hours needed by laboratory staff by up to 30%.

BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Retrieved on: 
Wednesday, June 7, 2023
Neutropenia, Platelet transfusion, RBC, IV, Multiple myeloma, Pegfilgrastim, Fever, Assistant, MS, ASCO, American Society of Clinical Oncology, Patient, Memorial Sloan Kettering Cancer Center, Annual general meeting, Drug discovery, MM, MSK, Toxic leukoencephalopathy, Principal, Melphalan, Society, Pharmaceutical industry, Blood product, MD, Plinabulin

BeyondSpring and Memorial Sloan Kettering Cancer Center (MSK) presented the data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting .

Key Points: 
  • BeyondSpring and Memorial Sloan Kettering Cancer Center (MSK) presented the data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting .
  • Between January 2022 and February 2023, 15 patients with a median age of 64 received Plinabulin after a high dose of melphalan.
  • The Plinabulin and pegfilgrastim combination appears well tolerated without additional major toxicities post AHCT.
  • “The Plinabulin-pegfilgrastim combination represents a new potential supportive care for MM patients undergoing AHCT.

Global Plasma Derived Therapies Market Report 2023: Sector is Expected to Reach $54.35 Billion by 2027 at a CAGR of 7.2% - ResearchAndMarkets.com

Retrieved on: 
Friday, May 26, 2023
Health, Biotechnology, Hepatitis B immune globulin, Prevalence, S.A, Face, Antibody, DSM-IV codes, Plasma, CSL Limited, AATD, Collection, Primary immunodeficiency, Growth, Neurology, Vaccine, Blood product, Octapharma

The market is expected to face certain challenges such as high cost and stringent regulations.

Key Points: 
  • The market is expected to face certain challenges such as high cost and stringent regulations.
  • The global plasma derived therapy market can be segmented as follows: Immunoglobulin, Hemophilia, Specialty, and Albumin.
  • The global plasma derived therapy market by region can be segmented into the following: North America, Europe, Asia Pacific, and LAMEA.
  • The report provides a comprehensive analysis of the global plasma derived therapy market, segmented into Immunoglobulin, Hemophilia, Specialty, and Albumin.

Freedom Plasma Hosts Ribbon Cutting and Open House

Retrieved on: 
Thursday, May 18, 2023
Medical Supplies, Health, Hospitals, Other Health, Managed Care, General Health, Biotechnology, Freedom, Plasma, Tourism, Television, Blood product

Freedom Plasma is hosting a ribbon cutting and open house to give people in the Roanoke area the chance to tour the state-of-the-art facility and learn more about the need for blood-plasma donations.

Key Points: 
  • Freedom Plasma is hosting a ribbon cutting and open house to give people in the Roanoke area the chance to tour the state-of-the-art facility and learn more about the need for blood-plasma donations.
  • Donated plasma is used to create many life-saving medicines and plasma-based treatments, and there is a tremendous demand for plasma worldwide.
  • The United States provides two-thirds of the world’s blood plasma.
  • The Roanoke Freedom Plasma center will help alleviate the shortage of plasma donations and will have an economic boost of approximately $5 million per year for the Roanoke community.